ABCG2: A perspective

Advanced Drug Delivery Reviews

Volumn 61, Issue 1, 2009, Pages 3-13

  Robey, Robert W ^a   To, Kenneth K K ^a   Polgar, Orsolya ^a   Dohse, Marius ^a   Fetsch, Patricia ^a   Dean, Michael ^b   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporter; ABCG2; BCRP; Chemotherapy; Drug resistance; Pharmacology

Indexed keywords

ABC TRANSPORTER; ABCG2; BCRP; DRUG-RESISTANCE; PHARMACOLOGY;

AMINO ACIDS; BIOCHEMISTRY; BLOOD; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG THERAPY;

CHEMOTHERAPY;

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; 9 AMINOCAMPTOTHECIN; ANTIVIRUS AGENT; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CARCINOGEN; CYCLOSPORIN; DOXORUBICIN; EDOTECARIN; ELACRIDAR; ERLOTINIB; FLAVONOID; FLAVOPIRIDOL; FUMITREMORGIN C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IRINOTECAN; METHOTREXATE; MITOXANTRONE; NICARDIPINE; NILOTINIB; NIMODIPINE; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; RHODAMINE; TARIQUIDAR; TOPOTECAN; UNINDEXED DRUG;

CANCER CELL; DRUG MEGADOSE; EPIGENETICS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; XENOBIOTIC METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; GENE EXPRESSION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 59049102086     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.11.003     Document Type: Review

References (159)

1. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
2. Biedler J.L., and Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30 (1970) 1174-1184
3. Akiyama S., Fojo A.T., Hanover J.A., and Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet. 11 (1985) 117-126
4. Kartner N., Riordan J.R., and Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221 (1983) 1285-1288
5. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455 (1976) 152-162
6. Roninson I.B., Chin J.E., Choi K., Gros P., Housman D.E., Fojo A., Shen D.-W., Gottesman M.M., and Pastan I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 4538-4542
7. Zhang Y., and Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40 (2001) 159-168
8. Deeken J.F., and Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13 (2007) 1663-1674
9. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
10. Bhalla K., Hindenburg A., Taub R.N., and Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res. 45 (1985) 3657-3662
11. Gervasoni Jr. J.E., Fields S.Z., Krishna S., Baker M.A., Rosado M., Thuraisamy K., Hindenburg A.A., and Taub R.N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 51 (1991) 4955-4963
12. Cole S.P., Downes H.F., and Slovak M.L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br. J. Cancer. 59 (1989) 42-46
13. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
14. Bakos E., and Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch. 453 (2007) 621-641
15. Leslie E.M., Deeley R.G., and Cole S.P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167 (2001) 3-23
16. Dietel M., Arps H., Lage H., and Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50 (1990) 6100-6106
17. Nakagawa M., Schneider E., Dixon K.H., Horton J., Kelley K., Morrow C., and Cowan K.H. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 human breast cancer cells. Cancer Res. 52 (1992) 6175-6181
18. Yang C.J., Horton J.K., Cowan K.H., and Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 55 (1995) 4004-4009
19. Chen Y.-N., Mickley L.A., Schwartz A.M., Acton E.M., Hwang J., and Fojo A.T. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem. 265 (1990) 10073-10080
20. Lee J.S., Scala S., Matsumoto Y., Dickstein B., Robey R., Zhan Z., Altenberg G., and Bates S.E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell. Biochem. 65 (1997) 513-526
21. Doyle L.A., Yang W., Abruzzo L.E., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. Cloning and characterization of breast cancer resistance protein (BCRP), a novel ATP-binding cassette (ABC) transporter that may contribute to the multidrug-resistance phenotype of MCF-7/AdrVp breast cancer cells. Proc. Am. Assoc. Cancer Res. 39 (1998)
22. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 (1998) 5337-5339
23. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., and Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59 (1999) 8-13
24. Rabindran S.K., He H., Singh M., Brown E., Collins K.I., Annable T., and Greenberger L.M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 58 (1998) 5850-5858
25. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8 (1992) 67-113
26. Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11 (2001) 1156-1166
27. Davidson A.L., and Chen J. ATP-binding cassette transporters in bacteria. Annu. Rev. Biochem. 73 (2004) 241-268
28. Annilo T., Chen Z.Q., Shulenin S., Costantino J., Thomas L., Lou H., Stefanov S., and Dean M. Evolution of the vertebrate ABC gene family: analysis of gene birth and death. Genomics 88 (2006) 1-11
29. Dean M., and Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6 (2005) 123-142
30. Mickley L., Jain P., Miyake K., Schriml L.M., Rao K., Fojo T., Bates S., and Dean M. An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain. Mamm. Genome 12 (2001) 86-88
31. Bailey-Dell K.J., Hassel B., Doyle L.A., and Ross D.D. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim. Biophys. Acta 1520 (2001) 234-241
32. Knutsen T., Rao V.K., Ried T., Mickley L., Schneider E., Miyake K., Ghadimi B.M., Padilla-Nash H., Pack S., Greenberger L., Cowan K., Dean M., Fojo T., and Bates S. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer 27 (2000) 110-116
33. Rao V.K., Wangsa D., Robey R.W., Huff L., Honjo Y., Hung J., Knutsen T., Ried T., and Bates S.E. Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. Cancer Genet. Cytogenet. 160 (2005) 126-133
34. Ee P.L., Kamalakaran S., Tonetti D., He X., Ross D.D., and Beck W.T. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 64 (2004) 1247-1251
35. Krishnamurthy P., Ross D.D., Nakanishi T., Bailey-Dell K., Zhou S., Mercer K.E., Sarkadi B., Sorrentino B.P., and Schuetz J.D. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279 (2004) 24218-24225
36. Szatmari I., Vamosi G., Brazda P., Balint B.L., Benko S., Szeles L., Jeney V., Ozvegy-Laczka C., Szanto A., Barta E., Balla J., Sarkadi B., and Nagy L. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem. 281 (2006) 23812-23823
37. Wang H., Lee E.W., Zhou L., Leung P.C., Ross D.D., Unadkat J.D., and Mao Q. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol. Pharmacol. 73 (2008) 845-854
38. Ebert B., Seidel A., and Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26 (2005) 1754-1763
39. Imai Y., Ishikawa E., Asada S., and Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res. 65 (2005) 596-604
40. Wang H., Zhou L., Gupta A., Vethanayagam R.R., Zhang Y., Unadkat J.D., and Mao Q. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E798-807
41. Yasuda S., Itagaki S., Hirano T., and Iseki K. Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J. Pharm. Pharm. Sci. 9 (2006) 133-139
42. To K.K., Zhan Z., and Bates S.E. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol. Cell. Biol. 26 (2006) 8572-8585
43. Turner J.G., Gump J.L., Zhang C., Cook J.M., Marchion D., Hazlehurst L., Munster P., Schell M.J., Dalton W.S., and Sullivan D.M. ABCG2 expression, function and promoter methylation in human multiple myeloma. Blood 108 (2006) 3881-3889
44. Nakanishi T., Bailey-Dell K.J., Hassel B.A., Shiozawa K., Sullivan D.M., Turner J., and Ross D.D. Novel 5′ untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Res. 66 (2006) 5007-5011
45. To K.K., Polgar O., Huff L.M., Morisaki K., and Bates S.E. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol. Cancer Res. 6 (2008) 151-164
46. To K.K., Zhan Z., Litman T., and Bates S.E. Regulation of ABCG2 expression at the 3′ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol. Cell. Biol. 28 (2008) 5147-5161
47. Yin L., Castagnino P., and Assoian R.K. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res. 68 (2008) 800-807
48. Evseenko D.A., Paxton J.W., and Keelan J.A. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab. Dispos. 35 (2007) 595-601
49. Ozvegy C., Litman T., Szakacs G., Nagy Z., Bates S., Varadi A., and Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 285 (2001) 111-117
50. Henriksen U., Gether U., and Litman T. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J. Cell Sci. 118 (2005) 1417-1426
51. Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T., and Sugimoto Y. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 97 (2002) 626-630
52. Graf G.A., Li W.P., Gerard R.D., Gelissen I., White A., Cohen J.C., and Hobbs H.H. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J. Clin. Invest. 110 (2002) 659-669
53. Diop N.K., and Hrycyna C.A. N-linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 44 (2005) 5420-5429
54. Henriksen U., Fog J.U., Litman T., and Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J. Biol. Chem. 280 (2005) 36926-36934
55. Russ W.P., and Engelman D.M. The GxxxG motif: a framework for transmembrane helix-helix association. J. Mol. Biol. 296 (2000) 911-919
56. Polgar O., Robey R.W., Morisaki K., Dean M., Michejda C., Sauna Z.E., Ambudkar S.V., Tarasova N., and Bates S.E. Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43 (2004) 9448-9456
57. Polgar O., Ozvegy-Laczka C., Robey R.W., Morisaki K., Okada M., Tamaki A., Koblos G., Elkind N.B., Ward Y., Dean M., Sarkadi B., and Bates S.E. Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Bichemistry 45 (2006) 5251-5260
58. Xu J., Peng H., Chen Q., Liu Y., Dong Z., and Zhang J.T. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res. 67 (2007) 4373-4381
59. McDevitt C.A., Collins R.F., Conway M., Modok S., Storm J., Kerr I.D., Ford R.C., and Callaghan R. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14 (2006) 1623-1632
60. Mogi M., Yang J., Lambert J.F., Colvin G.A., Shiojima I., Skurk C., Summer R., Fine A., Quesenberry P.J., and Walsh K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem. 278 (2003) 39068-39075
61. Takada T., Suzuki H., Gotoh Y., and Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab. Dispos. 33 (2005) 905-909
62. Fetsch P.A., Abati A., Litman T., Morisaki K., Honjo Y., Mittal K., and Bates S.E. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. (2005)
63. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (2001) 3458-3464
64. Diestra J.E., Scheffer G.L., Catala I., Maliepaard M., Schellens J.H., Scheper R.J., Germa-Lluch J.R., and Izquierdo M.A. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 198 (2002) 213-219
65. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., and Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
66. Zhang Y., Wang H., Unadkat J.D., and Mao Q. Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab. Dispos. 35 (2007) 2154-2158
67. Pollex E., Lubetsky A., and Koren G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29 (2008) 743-747
68. Zhou L., Naraharisetti S.B., Wang H., Unadkat J.D., Hebert M.F., and Mao Q. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol. Pharmacol. 73 (2008) 949-959
69. Gedeon C., Behravan J., Koren G., and Piquette-Miller M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 27 (2006) 1096-1102
70. Gedeon C., Anger G., Piquette-Miller M., and Koren G. Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta 29 (2008) 39-43
71. Staud F., Vackova Z., Pospechova K., Pavek P., Ceckova M., Libra A., Cygalova L., Nachtigal P., and Fendrich Z. Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J. Pharmacol. Exp. Ther. 319 (2006) 53-62
72. Myllynen P., Kummu M., Kangas T., Ilves M., Immonen E., Rysa J., Pirila R., Lastumaki A., and Vahakangas K.H. ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta. Toxicol. Appl. Pharmacol. 232 (2008) 210-217
73. Cooray H.C., Blackmore C.G., Maskell L., and Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13 (2002) 2059-2063
74. Hori S., Ohtsuki S., Tachikawa M., Kimura N., Kondo T., Watanabe M., Nakashima E., and Terasaki T. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J. Neurochem. 90 (2004) 526-536
75. Eisenblatter T., Huwel S., and Galla H.J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res. 971 (2003) 221-231 971
76. Zhang W., Mojsilovic-Petrovic J., Andrade M.F., Zhang H., Ball M., and Stanimirovic D.B. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17 (2003) 2085-2087
77. Cisternino S., Mercier C., Bourasset F., Roux F., and Scherrmann J.M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64 (2004) 3296-3301
78. Breedveld P., Pluim D., Cipriani G., Wielinga P., van Tellingen O., Schinkel A.H., and Schellens J.H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65 (2005) 2577-2582
79. Oostendorp R.L., Buckle T., Beijnen J.H., van Tellingen O., and Schellens J.H. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest. New Drugs (2008)
80. Bihorel S., Camenisch G., Lemaire M., and Scherrmann J.M. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J. Neurochem. 102 (2007) 1749-1757
81. Bihorel S., Camenisch G., Lemaire M., and Scherrmann J.M. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res. 24 (2007) 1720-1728
82. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., and van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res. 13 (2007) 6440-6449
83. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., Berns A.J., and Borst P. Disruption of mouse mdr-1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
84. Enokizono J., Kusuhara H., and Sugiyama Y. Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol. 72 (2007) 967-975
85. Jonker J.W., Merino G., Musters S., van Herwaarden A.E., Bolscher E., Wagenaar E., Mesman E., Dale T.C., and Schinkel A.H. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11 (2005) 127-129
86. van Herwaarden A.E., Wagenaar E., Karnekamp B., Merino G., Jonker J.W., and Schinkel A.H. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27 (2006) 123-130
87. Merino G., Jonker J.W., Wagenaar E., van Herwaarden A.E., and Schinkel A.H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol. 67 (2005) 1758-1764
88. Merino G., Alvarez A.I., Pulido M.M., Molina A.J., Schinkel A.H., and Prieto J.G. Breast Cancer Resistance Protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics and milk secretion. Drug Metab. Dispos. (2006)
89. Pulido M.M., Molina A.J., Merino G., Mendoza G., Prieto J.G., and Alvarez A.I. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J. Vet. Pharmacol. Ther. 29 (2006) 279-287
90. van Herwaarden A.E., Wagenaar E., Merino G., Jonker J.W., Rosing H., Beijnen J.H., and Schinkel A.H. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell. Biol. 27 (2007) 1247-1253
91. Olsen H.G., Nilsen H., Hayes B., Berg P.R., Svendsen M., Lien S., and Meuwissen T. Genetic support for a quantitative trait nucleotide in the ABCG2 gene affecting milk composition of dairy cattle. BMC Genet. 8 (2007) 32
92. Ron M., Cohen-Zinder M., Peter C., Weller J.I., and Erhardt G. Short communication: a polymorphism in ABCG2 in Bos indicus and Bos taurus cattle breeds. J. Dairy Sci. 89 (2006) 4921-4923
93. Bart J., Hollema H., Groen H.J., de Vries E.G., Hendrikse N.H., Sleijfer D.T., Wegman T.D., Vaalburg W., and van der Graaf W.T. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur. J. Cancer 40 (2004) 2064-2070
94. Enokizono J., Kusuhara H., Ose A., Schinkel A.H., and Sugiyama Y. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab. Dispos. 36 (2008) 995-1002
95. Gutmann H., Hruz P., Zimmermann C., Beglinger C., and Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 70 (2005) 695-699
96. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H.M., Koomen G.-J., and Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1 (2002) 417-425
97. Marchetti S., de Vries N.A., Buckle T., Bolijn M.J., van Eijndhoven M.A., Beijnen J.H., Mazzanti R., van Tellingen O., and Schellens J.H. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol. Cancer Ther. 7 (2008) 2280-2287
98. Sesink A.L., Arts I.C., de Boer V.C., Breedveld P., Schellens J.H., Hollman P.C., and Russel F.G. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. 67 (2005) 1999-2006
99. Kondo C., Onuki R., Kusuhara H., Suzuki H., Suzuki M., Okudaira N., Kojima M., Ishiwata K., Jonker J.W., and Sugiyama Y. Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm. Res. 22 (2005) 613-618
100. Seamon J.A., Rugg C.A., Emanuel S., Calcagno A.M., Ambudkar S.V., Middleton S.A., Butler J., Borowski V., and Greenberger L.M. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol. Cancer Ther. 5 (2006) 2459-2467
101. Zaher H., Khan A.A., Palandra J., Brayman T.G., Yu L., and Ware J.A. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm. 3 (2006) 55-61
102. van Herwaarden A.E., Jonker J.W., Wagenaar E., Brinkhuis R.F., Schellens J.H., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63 (2003) 6447-6452
103. Huls M., Brown C.D., Windass A.S., Sayer R., van den Heuvel J.J., Heemskerk S., Russel F.G., and Masereeuw R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 73 (2008) 220-225
104. Mizuno N., Suzuki M., Kusuhara H., Suzuki H., Takeuchi K., Niwa T., Jonker J.W., and Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos. 32 (2004) 898-901
105. Mizuno N., Takahashi T., Kusuhara H., Schuetz J.D., Niwa T., and Sugiyama Y. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Drug Metab. Dispos. 35 (2007) 2045-2052
106. Vander Borght S., Libbrecht L., Katoonizadeh A., van Pelt J., Cassiman D., Nevens F., Van Lommel A., Petersen B.E., Fevery J., Jansen P.L., and Roskams T.A. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J. Histochem. Cytochem. 54 (2006) 1051-1059
107. Aust S., Obrist P., Jaeger W., Klimpfinger M., Tucek G., Wrba F., Penner E., and Thalhammer T. Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab. Invest. 84 (2004) 1024-1036
108. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68 (2005) 800-807
109. Ando T., Kusuhara H., Merino G., Alvarez A.I., Schinkel A.H., and Sugiyama Y. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab. Dispos. 35 (2007) 1873-1879
110. Zamek-Gliszczynski M.J., Hoffmaster K.A., Humphreys J.E., Tian X., Nezasa K., and Brouwer K.L. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther. 319 (2006) 459-467
111. Zamek-Gliszczynski M.J., Nezasa K., Tian X., Kalvass J.C., Patel N.J., Raub T.J., and Brouwer K.L. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol. 70 (2006) 2127-2133
112. Enokizono J., Kusuhara H., and Sugiyama Y. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab. Dispos. 35 (2007) 209-214
113. Goodell M.A., Brose K., Paradis G., Conner A.S., and Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183 (1996) 1797-1806
114. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., and Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7 (2001) 1028-1034
115. Scharenberg C.W., Harkey M.A., and Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99 (2002) 507-512
116. Jonker J.W., Buitelaar M., Wagenaar E., Van Der Valk M.A., Scheffer G.L., Scheper R.J., Plosch T., Kuipers F., Elferink R.P., Rosing H., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15649-15654
117. Zhou S., Morris J.J., Barnes Y., Lan L., Schuetz J.D., and Sorrentino B.P. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12339-12344
118. Polgar O., Robey R.W., and Bates S.E. ABCG2: structure, function and role in drug response. Expert Opin. Drug Metab. Toxicol. 4 (2008) 1-15
119. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., Litman T., Dean M., and Bates S.E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61 (2001) 6635-6639
120. Robey R.W., Honjo Y., Morisaki K., Nadjem T.A., Runge S., Risbood M., Poruchynsky M.S., and Bates S.E. Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89 (2003) 1971-1978
121. Ejendal K.F., Diop N.K., Schweiger L.C., and Hrycyna C.A. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 15 (2006) 1597-1607
122. Miwa M., Tsukahara S., Ishikawa E., Asada S., Imai Y., and Sugimoto Y. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int. J. Cancer 107 (2003) 757-763
123. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., and Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60 (2000) 47-50
124. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., and Baer M.R. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin. Cancer Res. 11 (2005) 2320-2326
125. de Bruin M., Miyake K., Litman T., Robey R., and Bates S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 146 (1999) 117-126
126. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., and Bates S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64 (2004) 1242-1246
127. Minderman H., O'Loughlin K.L., Pendyala L., and Baer M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10 (2004) 1826-1834
128. Mukai M., Che X.F., Furukawa T., Sumizawa T., Aoki S., Ren X.Q., Haraguchi M., Sugimoto Y., Kobayashi M., Takamatsu H., and Akiyama S. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci. 94 (2003) 557-563
129. Houghton P.J., Germain G.S., Harwood F.C., Schuetz J.D., Stewart C.F., Buchdunger E., and Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64 (2004) 2333-2337
130. Liu W., Baer M.R., Bowman M.J., Pera P., Zheng X., Morgan J., Pandey R.A., and Oseroff A.R. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin. Cancer Res. 13 (2007) 2463-2470
131. Ozvegy-Laczka C., Hegedus T., Varady G., Ujhelly O., Schuetz J.D., Varadi A., Keri G., Orfi L., Nemet K., and Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65 (2004) 1485-1495
132. Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., Goldman J.M., and Melo J.V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
133. Ferrao P.T., Frost M.J., Siah S.P., and Ashman L.K. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 102 (2003) 4499-4503
134. Jordanides N.E., Jorgensen H.G., Holyoake T.L., and Mountford J.C. Functional ABCG2 is over-expressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood (2006)
135. Brendel C., Scharenberg C., Dohse M., Robey R.W., Bates S.E., Shukla S., Ambudkar S.V., Wang Y., Wennemuth G., Burchert A., Boudriot U., and Neubauer A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21 (2007) 1267-1275
136. Shukla S., Sauna Z.E., and Ambudkar S.V. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 22 (2008) 445-447
137. Tamura A., Onishi Y., An R., Koshiba S., Wakabayashi K., Hoshijima K., Priebe W., Yoshida T., Kometani S., Matsubara T., Mikuriya K., and Ishikawa T. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab. Pharmacokinet. 22 (2007) 428-440
138. Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., Miki Y., and Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1 (2002) 611-616
139. Mizuarai S., Aozasa N., and Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 109 (2004) 238-246
140. Morisaki K., Robey R.W., Ozvegy-Laczka C., Honjo Y., Polgar O., Steadman K., Sarkadi B., and Bates S.E. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56 (2005) 161-172
141. Tamura A., Watanabe M., Saito H., Nakagawa H., Kamachi T., Okura I., and Ishikawa T. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol. Pharmacol. 70 (2006) 287-296
142. Sparreboom A., Loos W.J., Burger H., Sissung T.M., Verweij J., Figg W.D., Nooter K., and Gelderblom H. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer. Biol. Ther. 4 (2005) 650-658
143. Sparreboom A., Gelderblom H., Marsh S., Ahluwalia R., Obach R., Principe P., Twelves C., Verweij J., and McLeod H.L. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 76 (2004) 38-44
144. Zamboni W.C., Ramanathan R.K., McLeod H.L., Mani S., Potter D.M., Strychor S., Maruca L.J., King C.R., Jung L.L., Parise R.A., Egorin M.J., Davis T.A., and Marsh S. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest. New Drugs 24 (2006) 393-401
145. Lepper E.R., Nooter K., Verweij J., Acharya M.R., Figg W.D., and Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6 (2005) 115-138
146. Rudin C.M., Liu W., Desai A., Karrison T., Jiang X., Janisch L., Das S., Ramirez J., Poonkuzhali B., Schuetz E., Fackenthal D.L., Chen P., Armstrong D.K., Brahmer J.R., Fleming G.F., Vokes E.E., Carducci M.A., and Ratain M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26 (2008) 1119-1127
147. Ross D.D., Karp J.E., Chen T.T., and Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96 (2000) 365-368
148. Robey R.W., Polgar O., Deeken J., To K.W., and Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis. Rev. 26 (2007) 39-57
149. Benderra Z., Faussat A.M., Sayada L., Perrot J.Y., Chaoui D., Marie J.P., and Legrand O. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10 (2004) 7896-7902
150. Wilson C.S., Davidson G.S., Martin S.B., Andries E., Potter J., Harvey R., Ar K., Xu Y., Kopecky K.J., Ankerst D.P., Gundacker H., Slovak M.L., Mosquera-Caro M., Chen I.M., Stirewalt D.L., Murphy M., Schultz F.A., Kang H., Wang X., Radich J.P., Appelbaum F.R., Atlas S.R., Godwin J., and Willman C.L. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108 (2006) 685-696
151. Leonard G.D., Polgar O., and Bates S.E. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs 3 (2002) 1652-1659
152. M. Garcia-Closas, S.J. Chanock, Genetic susceptibility loci for beast cancer by esgtrogen reseptor (ER) status. Clin Cancer Res (in press).
153. Pan J.H., Han J.X., Wu J.M., Sheng L.J., Huang H.N., and Yu Q.Z. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75 (2008) 380-385
154. Kafka A., Sauer G., Jaeger C., Grundmann R., Kreienberg R., Zeillinger R., and Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22 (2003) 1117-1121
155. Jamroziak K., Mlynarski W., Balcerczak E., Mistygacz M., Trelinska J., Mirowski M., Bodalski J., and Robak T. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 72 (2004) 314-321
156. Cusatis G., Gregorc V., Li J., Spreafico A., Ingersoll R.G., Verweij J., Ludovini V., Villa E., Hidalgo M., Sparreboom A., and Baker S.D. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 98 (2006) 1739-1742
157. Apperley J.F. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8 (2007) 1116-1128
158. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., and Mahon F.X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
159. Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., Robak T., Khoroshko N., Masszi T., Skotnicki A., Hellmann A., Zaritsky A., Golenkov A., Radich J., Hughes T., Countouriotis A., and Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109 (2007) 5143-5150